Enterprise Value to EBITDA Ratio: Ikena (IKNA)

Ikena Oncology Inc. (IKNA) - corporate logo

The price action for Ikena Oncology, Inc. (IKNA) shown on this chart demonstrates an EV/EBITDA ratio of . The business is penetrating markets for scarce oncology therapies by conducting trials to recruit its first patients. The firm is implementing AI-driven biomarker analysis and studying cell death to combat resistant neoplasms. The strategy's success relies on investor confidence and the precision of targeting genetic disease development chains.

IKNA Ikena Oncology: Business Value to Operating Income Before Depreciation in the range 07/04/2022 - 11/17/2026

Analytical breakdowns for Ikena Oncology, Inc.

- current price and projected stock value:
- company stock exchange capitalization indicators:
Fundamental company analysis:Ikena IKNA
Product sample of Ikena Oncology

Ikena Oncology, Inc. (IKNA) develops targeted cancer therapies, relying on external financing due to a lack of recurring revenue. By analyzing the EV/EBITDA trend over time, an investor compares the total enterprise value of the business with its operating profit before interest, taxes, depreciation, and amortization. An upward trajectory of this curve signals rising market expectations regarding the company's future success, while simultaneously warning of the risk of overpaying for the asset.

Competitor analysis

BeiGene Oncology - Enterprise Value to EBITDA Ratio|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology Corp (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen - Business Value to Operating Income Before Depreciation|BCAX (Bicara Therapeutics Inc) - EV/EBITDA Multiple|Company Value to EBITDA personalis.com PSNL|EV/EBITDA Multiple ERAS|Delcath Systems - Enterprise Value to Operating Income Before Depreciation|Y-mAbs Therapeutics Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Aura Corp AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Accuray (ARAY) - Enterprise Value to EBITDA Ratio|SLS: EV/EBITDA Multiple|Actuate Therapeutics (ACTU) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CTOR|HURA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara Therapeutics (TARA)|Enterprise Value to Operating Income Before Depreciation Ratio FATE|EV/EBITDA Multiple WHWK (aadibio.com)|Enterprise Value to Operating Income Before Depreciation Ratio TCRX (TScan)|CSBR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation XBIT (XBiotech Inc)|cel-sci.com (CVM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio OSTX (OS Therapies Incorporated)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Radiopharm Theranostics Ltd|Company Value to EBITDA Artiva Biotherapeutics ARTV|EV/EBITDA Multiple ANL|VERU - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Therapeutics TPST|xiliotx.com (XLO) - Company Value to EBITDA|RENB: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Mural Oncology PLC (MURA)|KAPA (Kairos Pharma Inc) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA OnKure Therapeutics Inc (OKUR)|GDTC (CytoMed Therapeutics Ltd) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Curis, Inc. (CRIS)|EV/EBITDA Multiple APLM|Enterprise Value to Operating Income Before Depreciation Ratio THAR|EV/EBITDA Multiple ADVB (advanbiomed.com)|GNPX - Enterprise Value to EBITDA Ratio|CLDI: Enterprise Value to EBITDA Ratio|SBFM - EV/EBITDA Multiple|Xenetic Biosciences (XBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SLRX: Enterprise Value to Operating Income Before Depreciation Ratio|PPBT (Purple Biotech Ltd) - EV/EBITDA Multiple|Company Value to EBITDA American Oncology Network, Inc. AONC|EV/EBITDA Multiple BGNE|Total Company Value to Operating Income Before Depreciation Ratio Checkpoint Therapeutics|Elevation Oncology, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple iCAD, Inc. ICAD|Notable Labs Ltd - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics Inc.)|MorphoSys AG (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio NAYA Biosciences|AAPGV (ascentage.com) - EV/EBITDA Multiple